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Abstract
Atopic dermatitis (AD) is an inflammatory, pruritic and chronic allergic skin disease. It is recognized as the second-
most common allergic skin disease of dogs, after flea allergy. Pruritus is the predominant sign of canine AD, and it 
affects a variety of areas of the body, leading to intense suffering in both the animal and its owner. The long-term use 
of glucocorticoid therapy can be devastating because of its numerous side effects and secondary diseases. Cyclosporine 
(CsA) has been considered a good therapeutic option to treat canine AD. CsA inhibits the activation of cells that initiate 
the cutaneous immune response (Langerhans cells and lymphocytes) and that mediate allergic reactions (mast cells and 
eosinophils). It also decreases the release of histamine and other cytokines. The objective of this study was to analyze 
the efficacy of CsA (5 mg/kg, SID for 60 days) to reduce skin lesions and pruritus in 21 atopic dogs using CADESI-03 
and two scales to quantify the levels of body itching. This immunomodulatory therapy was considered to be an effective 
treatment for atopic dogs because it reduced skin lesions by 70% after 60 days of therapy. During that period, there 
was a 52.6% reduction of body itching as assessed via a verbal numeric scale, and there was a significant reduction of 
body itching on a qualitative scale, as the maximal levels of pruritus (“three” and “four”) were hardly observed after 
immunomodulatory therapy. CsA was effective and safe in the treatment of canine atopic dermatitis. 
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Resumo
A atopia ou dermatite atópica é uma doença inflamatória pruriginosa, crônica e recorrente reconhecida como a segunda 
alergopatia mais comum, estando aquém apenas da dermatite alérgica à picada de pulgas. Esta doença é caracterizada 
pela presença exacerbada de prurido corpóreo, infringindo sofrimento ao paciente e desalentando seu proprietário. Por 
se tratar de uma doença de longo decurso, o tratamento com glicocorticoides pode causar diversos efeitos adversos, além 
de doenças mais graves. Como alternativa ao tratamento de cães atópicos, a ciclosporina (CsA) acaba tornando-se uma 
boa opção terapêutica. A CsA inibe as funções das células que iniciam a resposta imunológica (células de Langerhans 
e linfócitos) e das células que efetuam a resposta alérgica (mastócitos e eosinófilos) e, também, diminui a liberação de 
histamina e de várias citocinas. O objetivo do presente estudo incluiu a: análise da eficácia da CsA (5mg/kg, SID durante 
60 dias) na redução de lesões corpóreas e do prurido com auxílio do CADESI-03 e de duas escalas de prurido corpóreo. 
A CsA mostrou-se eficaz no tratamento da dermatite atópica canina pois reduziu as lesões corpóreas em 70% após 60 
dias de terapia. Nesse mesmo período ocorreu redução da intensidade do prurido corpóreo em 52,6%, avaliado através 
da escala numérica verbal; e observou-se redução significativa na escala qualitativa de prurido corpóreo, uma vez que 
os níveis máximos de prurido (“três” e “quatro”) quase não foram observados após a terapia imunomodulatória. A CsA 
mostrou-se eficaz no tratamento da dermatite atópica canina. 
Palavras-chave: Dermatite atópica. Prurido. Ciclosporina. Cães.
Introduction
Atopic dermatitis (AD) is a common dermatosis 
that affects dogs and is defined as an inflammatory 
pruritic dermatopathy. It is chronic and recurrent and 
genetically determined, with characteristic clinical 
manifestations usually associated with the production 
of IgE antibodies, which are specific for environmen-
tal allergens1.
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Currently, a new class of AD is being proposed that 
should be differentiated from AD: “atopic dermatitis-
like” (AD-like) disease. AD-like disease presents the 
same clinical manifestations as AD, but the presence 
of IgE antibodies specific against environmental aller-
gens has not been fully confirmed2,3,4.
AD affects between 3 to 15% of the canine popula-
tion5,6,7. 
Due to chronic and relapsing characteristics of AD 
and the fact that it drastically reduces the quality of 
life of its carriers, there is a constant need to study dif-
ferent therapeutic approaches with the goal of replac-
ing chronic corticosteroid use due to their devastating 
side effects. 
Cyclosporine (CsA) is a liposoluble cyclic polypep-
tide metabolite derived from the fungus Tolypocladi-
uminflatum gams. This drug forms a complex with an 
intracellular protein, cyclophilin-1, and this complex 
in turn inhibits calcineurin, an enzyme that synthe-
sizes IL-2. The absence of this interleukin hinders 
the activation and proliferation of T lymphocytes as 
compared to other cytokines, such as IL-4 and INF-γ. 
Other characterized effects of CsA include its ability 
to decrease the survival and degranulation of mast 
cells; inhibit the release of IL-4, IL-5, TNF, IL-3 and 
IL-8; inhibit eosinophil survival and recruitment to 
the site of inflammation; decrease the number and 
antigen-presenting function of Langerhans cells; de-
crease the release of keratinocyte cytokines; decrease 
mast cell-dependent cellular infiltration; and decrease 
IgE in cutaneous inflammation sites by preventing the 
TNF-mediated late-phase reactions8,9.
In veterinary medicine, CsAis indicated for the 
control of immunomediated and autoimmune dis-
eases, such as perianal fistulas, complex pemphigus, 
pemphigoid-bullous, sebaceous adenitis, atopic der-
matitis, sterile nodular panniculitis, alopecia areata 
and Sézary syndrome, among others10,11. The effica-
cy and safety of CsA for the control of AD has been 
documented by several foreign and Brazilian au-
thors12,13,14,15,16,17,18. 
The present study aimed to evaluate the efficacy of 
oral administration of CsA (5 mg/kg, SID for 60 days) 
in the treatment of AD through the evaluation of the 
score of corporal lesions and two different scales of 
pruritus using the case series of the Dermatology Di-
vision (DD) of the Department of Clinical Medicine 
(DCM) and the Veterinary Hospital (VETHO) of the 
School of Veterinary Medicine and Zootechnology of 
the University of São Paulo (Faculdade de Medicina-
Veterinária e Zootecnia da Universidade de São Paulo 
– FMVZ/USP).
Material and Method
The experimental group included 21 dogs with AD 
diagnosed by the DD of the DCM VETHO of the 
FMVZ/USP without any restriction regarding breed, 
gender or age.    
Dogs with a pre-established diagnosis of AD with 
moderate (“grade” 5 or 6) or intense (“grade” 7-10) 
manifestations of body pruritus (seasonal or peren-
nial), as determined by the verbal numerical rating 
scale, and with level three or four pruritus, as deter-
mined by the body pruritus qualitative scale as pro-
posed by Hill19 and its subsequent modifications (Ap-
pendix A), were selected. The following animals were 
included in the study or removed during the course 
of the study: carriers of epilepsy, nephropathy or he-
matopathy; those from owners or representatives not 
aware of the clinical condition, temper, mode of con-
duct or correct handling, hygiene and sanitation of 
the patients; those with known previous conditions 
of altered blood pressure, hematic background or se-
rum biochemistry; those not properly submitted to 
the experimental protocol or clinical follow-up; and 
those seropositive for leishmaniasis. For inclusion in 
the experimental study, a diagnosis of AD was made 
based on the symptomatic and lesion features and by 
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excluding other primary mimetic pruritic dermatopa-
thies (scabies, tropho-allergic dermatitis or siphonap-
tera bites) via additional examination. 
The devised protocol involved the application of 
cyclosporine (SandimmunNeoral® – Novartis, oral 
solution, 100 mg/mL) at a dosage of 5 mg/kg weight, 
per os, every 24 hours for 60 days. Assessments were 
performed 15, 30 and 60 days after the first appoint-
ment (Day 0).
Bathing was recommended every 5 days using warm 
water and emollient soap (Dove®) followed by rinsing 
with plenty of water and drying without the aid of a hot 
blow dryer. Animals presenting secondary pyoderma 
underwent systemic antibiotic therapy (amoxicillin 
with potassium clavulanate, per os) at the standard dos-
age of the DD (DCM-VETHO/USP). This drug was se-
lected due to the lower risk of emetic episodes so as not 
to interfere with the effects of CsA therapy.
During the course of the study, all animals were 
submitted to a strict control of ticks and fleas using 
the ectoparasiticide(Advantage max 3®) commonly 
employed in the therapy scheme and the standard 
prophylactic of the DD. 
The protocol was suspended and orthodox steroid 
therapy was adoptedwhenever side effects appeared 
(tegumentary or systemic), the protocol proved inef-
fective or as specifically requested by the owner. 
The animals under anti-pruritic steroid therapy at the 
time the study were gradually (≤ 21 days) withdrawn 
simultaneosly with the introduction of the new proto-
col. Isolated cyclosporine therapy was also performed 
over the same period at the end of the study.
On the first appointment and on the three subse-
quent scheduled visits, the following analyses were 
performed:
a) Classification and quantification of skin lesions 
using the Canine Atopic Dermatitis Extent and Se-
verity Index (CADESI-03) score20, which is a scale of 
severity from 0 to 5. A total of 62 different body re-
gions were analyzed. CADESI-03 was used on the first 
appointment and on the scheduled rechecks 30 and 
60 days later. If on the last visit (Day 60) the subject 
presented a 50% or greater decrease in theCADESI-03 
score, a recommendation was made to administer cy-
closporine  every 48 hours.
b) Determination of the presence and/or the inten-
sity of pruritic symptoms at the time of enrollment 
and during clinical follow-up. Pruritus was assessed by 
interviewing the owners or representatives using the 
verbal numerical scale and qualitative levels modified 
from those originally proposed by Hill19. This evalu-
ation was performed at Days 0 (first appointment), 
15, 30 and 60. Qualitative levels of body pruritus were 
included in the circular graphical representation (Fig-
ure 1) so that owners would not confine themselves to 
use just the numerical pruritus scale but would also be 
aware to behavioral changes.
For the qualitative variables, absolute (n) and relative 
(%) frequencies were presented; for the quantitative vari-
ables, the mean and median were calculated as a summary 
metric. The minimum, maximum and standard deviation 
values were used as measures of variability. 
The data for quantitative variables were compared 
at the different stages (D- 0, D- 15, D- 30, D- 60), and 
a repeated measures analysis of variance was used as 
the statistical test. The results are shown below each 
table of the following section at a significance level of 
5%; i.e., the significance is indicated by a p-value < 
0.05 (highlighted in blue). To use this test, the group 
variance homogeneity was evaluated, which is a nec-
essary assumption. If a difference between stages was 
detected, multiple comparisons were performed to 
identify which groups differed (paired comparisons 
at the different stages) by the Bonferroni test. A sig-
nificance level of 5% was also used for this test.
Results
Thirty-nine dogs, without any restriction of breed, 
gender or age and with a set diagnosis of AD, were 
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enrolled in the study. From these, 18 were excluded 
for meeting at least one of the previously described 
exclusion criteria. The remaining 21 animals followed 
the protocol to completion.
The summary metrics (value and median) and 
measures of variance (minimum, maximum and stan-
dard deviation) of the quantitative variables (age and 
weight) did not change throughout the trial. However, 
some statistically significant differences (p < 0.05) in 
CADESI-03 score values were observed at different 
time points (Days 0, 30 and 60), and the highest value 
was obtained at the start of the study (Table 1).
As assessed by the verbal numerical scale, chang-
es were observed in body pruritus at the different 
times of evaluation (Table 2). Multiple comparisons 
revealed  statistically significant changes (p < 0.001) 
between the starting stage and the remaining stages, 
with larger values in the pruritus scale than the rest. 
There was also a difference in the pruritus values be-
tween Days 15 and 60. However, no significant differ-
ences were observed between the follow-ups at Days 
15 and 30 or between Days 30 and 60.
Regarding body pruritus as assessed by the quali-
tative pruritus scale, there were also differences be-
tween the defined stages (Table 3). A significance 
level of 5% was used; i.e., a difference was considered 
significant at a p-value < 0.05. At the first stage, there 
was a higher percentage of high values of the scale as 
compared with the other stages. At Day 0, there were 
no values of 0 or 1 on this scale.
After 60 days of treatment with CsA, 11 out of the 
21 dogs (52.4%) presented a decrease in the CADE-
SI-03 score of at least 50%. For this subset of speci-
mens, CsA was subsequently administered once every 
48 hours. Six dogs (28.6%) did not show the expected 
signs of improvement and continued to receive CsA 
on a daily basis. Treatment was interrupted for four 
specimens (19%) during the last check-up step either 
due to an evident improvement of their clinical pic-
ture and/or at the owner’s request, as the high cost of 
the drug would have to be supported exclusively by 
the owner.
Discussion
Tegumentary lesions as quantified by CADESI-03 
were significantly reduced when comparing the start-
ing stage (D- 0) to the other stages (D- 30 and D- 60). 
After 30 days of CsA treatment, a 52.3% decrease in 
the CADESI-03 index was observed. After 60 days, 
this decrease reached 70%. These data proves the ef-
ficacy of CsA in reducing the number of skin lesions 
(primary or crusted) stemming from AD, which is 
in agreement with previous studies12,13,14,15,17. In the 
present study, a larger percentage of lesion involution 
occurred in the first 30 days, as was observed in the 
study by Steffan, Parks and Seewald17.
Pruritus assessment via the verbal numerical scale 
revealed a statistically significant difference between 
the starting stage (D- 0) and the remaining stages (D- 
30 and D- 60) and also between Day 15 and Day 60.
After 15 days of CsA treatment, a gradual decrease 
of up to 36% in pruritus intensity was observed. This 
percentage increased to 45% and 52.6% after 30 and 
60 days, respectively, proving the efficacy of CsA in 
the relief of this symptom.
The results obtained using the body pruritus quali-
tative scale revealed a statistically significant differ-
ence between the different stages. On Day 0, pruri-
tus level “three” was the most common (57.1%), fol-
lowed by levels “four” (23.8%) and “two” (19%). On 
Day 60, level “one,” which had not been observed on 
Day 0, became the most prevalent (47.6%), followed 
by levels “zero” (28.6%), “two” and “four” (9.5% each) 
and “three” (4.8%). Therefore, after 60 days of CsA 
therapy, the incidence of the maximum level of pru-
ritus, level “four,” had decreased from 23.8% to 9.5%, 
whereas the incidence of level “three” decreased from 
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57.1% to 4.8%. These results clearly indicate a signifi-
cant improvement of body pruritus as assessed by an-
other less subjective scale. 
Fontaine and Olivry12 reported a 100% decrease in 
the magnitude of pruritus after 14 days of treatment. 
The authors reported a larger decrease in the pruri-
tus score as compared to the lesion score, which  de-
creased by 60%. This might be due to the shorter time 
span of that study, which was insufficient to allow evi-
dent remission of chronic lesions. 
Mean Median Standard Deviation Minimum Maximum
Day 0 48.3 26.0 58.6 8.0 272.0
Day 30* 25.3 15.0 25.6 0.0 106.0
Day 60* 14.5 15.0 14.2 0.0 42.0
p-value = 0.040
*statistically significant difference (p < 0.05) relative to the starting point.
Table 1 –  Mean CADESI-03 scores for body lesions in dogs with atopic 
dermatitis undergoing cyclosporine therapy. DD, VETHO- 
FMVZ/USP - São Paulo - 2010
Mean Median Standard Deviation Minimum Maximum
Day 0 7.8 8.0 1.0 5.0 9.0
Day 15* 5.0 5.0 2.0 1.0 8.0
Day 30* 4.3 4.0 2.2 1.0 8.0
Day 60*# 3.7 3.0 2.3 0.0 8.0
p-value <0.001
*statistically significant difference (p < 0.05) relative to the Day 0 value.
#statistically significant difference (p < 0.05) relative to the Day 15 value.
Table 2 – Mean values of pruritus intensity as assessed via the verbal 
numerical scale of dogs with atopic dermatitis undergoing 
cyclosporine therapy. DD, VETHO – FMVZ/USP - São Paulo 
-2010
Scale
Day 0 15 days* 30 days* 60 days*
n % n % n % n %
0 - - 2 9.5 6 28.6 6 28.6
1 - - 13 61.9 9 42.9 10 47.6
2 4 19.0 3 14.3 4 19.0 2 9.5
3 12 57.1 2 9.5 - - 1 4.8
4 5 23.8 1 4.8 2 9.5 2 9.5
p-value < 0.001
*statistically significant difference (p < 0.05) relative to Day 0.
Table 3 – Mean values of pruritus intensity (n and %) as assessed by 
the qualitative scale of atopic dermatitis in dogs undergoing 
cyclosporine therapy. DD of VETHO – FMVZ/USP - São 
Paulo - 2010
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short time span of their study would be insufficient to 
allow evident involution of chronic lesions.
Conclusion
Regarding the methodology employed in this study, 
it is possible to conclude that per osCsA therapy at a 
single daily dosage of5 mg/kg for 60 consecutive days 
constitutes an effective  pharmaceutical option be-
cause of the following:
- it initiated and maintained a decrease in body 
pruritus as measured by qualitative and quantitative 
scores (verbal and qualitative numerical scales) after 
15, 30, and 60 days of therapy, and
- it resulted in a decrease of elementary skin lesions 
according to a score of extent and severity (CADE-
SI-03), after 30 and 60 days of treatment.
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Figure 1 - Qualitative levels of body pruritus. Modified (Hill)19
